PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) said detailed clinical data from early-stage studies of its long-acting hormone-suppressing drug Teverelix have been accepted for presentation at a major international endocrinology conference, signaling growing momentum for the experimental therapy across multiple disease areas.
The company said results from two randomized, placebo-controlled Phase 1 studies of Teverelix will be presented as an e-poster at the American Association of Clinical Endocrinology Annual Meeting 2026, scheduled for April 22–24 in Las Vegas. The studies evaluated the pharmacokinetics, pharmacodynamics, bone turnover effects, and safety of the drug in 48 healthy premenopausal women.
According to the accepted abstract, single subcutaneous injections of Teverelix produced rapid suppression of key reproductive hormones, including luteinizing hormone and follicle-stimulating hormone, within 24 hours. Estradiol suppression was dose-dependent and reversible, with several participants reaching hormone levels associated with symptom control while limiting bone loss risk.
Researchers also reported sustained hormone suppression lasting up to two to three weeks at higher doses, stable bone turnover markers over the one-month follow-up period, and a favorable safety profile. No drug-related serious adverse events were observed, and reported side effects were mild to moderate.
“We believe that these findings reinforce the versatility of Teverelix as a long-acting GnRH antagonist platform,” said Dr. Raza Bokhari, Medicus’ executive chairman and chief executive officer. He said the data support expanding development beyond the drug’s existing programs in prostate cancer and acute urinary retention relapse prevention into women’s health, including endometriosis.
Endometriosis affects an estimated 10% of women of reproductive age worldwide and often requires therapies that balance hormone suppression with long-term safety, particularly related to bone health. Medicus said it is engaged in regulatory planning for a genomics-informed Phase 2 study of Teverelix in women with symptomatic endometriosis in the United Arab Emirates.
Teverelix is a long-acting injectable gonadotropin-releasing hormone antagonist formulated as a microcrystalline suspension. Unlike older GnRH agonists, which can cause an initial hormone surge, the drug immediately blocks the receptor, allowing rapid suppression without a flare effect. Medicus said this mechanism could be particularly relevant for prostate cancer patients with elevated cardiovascular risk, although further validation is required.
The company said its broader strategy is to advance select assets through Phase 2 proof-of-concept studies before pursuing licensing or strategic partnerships for late-stage development and commercialization.
Alongside Teverelix, Medicus continues to advance SkinJect, a dissolvable microneedle platform delivering doxorubicin for the non-invasive treatment of basal cell carcinoma. Phase 2 enrollment for that program has been completed, with topline data expected in the first quarter of 2026 and an end-of-Phase 2 meeting with the U.S. Food and Drug Administration planned for the first half of the year.
Medicus said it is assembling decision-grade clinical and regulatory data across its portfolio as it positions multiple programs for the next stage of development.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.